We Live GI

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.

We have pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders.  We discovered, are developing and control 100% worldwide rights to our proprietary uroguanylin based GI platform that includes one commercial product, TRULANCE™ (plecanatide), and a second lead product candidate, dolcanatide.

We are based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Synergy [SGYP] became a public company in July 2008 and is currently listed on NASDAQ.

What Matters To Us

At Synergy, our values guide every aspect of our business—from our relationships with customers to how we approach science and innovation, and to realizing our vision of a healthier future for patients.

We see GI Differently

At Synergy Pharmaceuticals, we have a different perspective in gastrointestinal (GI) science. With our novel approach, we are redefining how GI conditions, diseases, and disorders are treated.

Igniting Change for new solutions

At Synergy, we’re challenging the status quo in GI to develop new treatments that offer the potential to change people’s lives.

We see GI Differently

At Synergy Pharmaceuticals, we have a different perspective in gastrointestinal (GI) science. With our novel approach, we are redefining how GI conditions, diseases, and disorders are treated.

Innovation Begins with uncovering insights

We dig deeper to discover breakthrough solutions for unmet needs in the GI category.

We see GI Differently

At Synergy Pharmaceuticals, we have a different perspective in gastrointestinal (GI) science. With our novel approach, we are redefining how GI conditions, diseases, and disorders are treated.

Fighting for Patients is at our core

With our novel approach to GI science, we are focused on the development of novel therapies that offer the potential to address patient needs.

Contact Us

Synergy Pharmaceuticals Inc.
420 Lexington Avenue
Suite 2012
New York, NY 10170
Phone: [+1] 212-297-0020
Fax: [+1] 212-297-0019

*Required field